A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects With Schizophrenia
Latest Information Update: 05 Sep 2023
At a glance
- Drugs Talnetant (Primary) ; Risperidone
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 06 Oct 2006 Status change
- 09 Oct 2005 New trial record.